Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

2025-522345-21-00 Protocol A148_01PK2408 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 11 Nov 2025 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol A148_01PK2408

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 213
Countries 1
Sites 1

Active psoriatic arthritis

Key facts

Sponsor
Chong Kun Dang Pharmaceutical Corp.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
11 Nov 2025 → ongoing
Decision date (initial)
2025-10-26
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Active psoriatic arthritis

VersionLevelCodeTermSystem organ class
21.0 LLT 10037160 Psoriatic arthritis 10028395
20.0 LLT 10071117 Plaque psoriasis 10040785
20.0 PT 10009900 Colitis ulcerative 100000004856
28.0 PT 10011401 Crohn´s disease 100000004856

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Chong Kun Dang Pharmaceutical Corp.

Sponsor organisation
Chong Kun Dang Pharmaceutical Corp.
Address
8 Chungjeong-Ro
City
Seodaemun
Postcode
03742
Country
Korea, Republic of

Scientific contact point

Organisation
Chong Kun Dang Pharmaceutical Corp.
Contact name
Soung-Jun Min, M.D.

Public contact point

Organisation
Chong Kun Dang Pharmaceutical Corp.
Contact name
Eunsu Jung

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ongoing, recruitment ended 213 1
Rest of world 0

Investigational sites

Poland

1 site · Ongoing, recruitment ended
Mtz Clinical Research Powered By Pratia
N/A, Ul. Gładka 22, 02-172, Warsaw

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2025-11-11 2025-11-12 2026-03-19

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-03 Poland Acceptable
2025-10-20
2025-10-26
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-15 Poland Acceptable
2025-10-20
2025-12-15